NTNguyen Huong Giang Trinh

Nguyen Huong Giang Trinh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nguyen Huong Giang Trinh has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Benchmarking Deep Learning for NSCLC PET/CT Segmentation on a Histologically Confirmed Vietnamese Dataset: Validation and Generalization

    by Quang Tuan Ho, Ngoc Ha Bui, Thuy Duong Tran, Quang Huy Khuat, Ngoc Toan Tran, Xuan Chung Le, Huu Quyet Nguyen, Tat Thang Nguyen, Van Thai Nguyen, Dinh Thuy Mai, et al.

    Accurate segmentation of non-small cell lung cancer (NSCLC) on positron emission tomography/computed tomography (PET/CT) is an essential prerequisite for automated metabolic tumor volume (MTV) quantification and staging. Although deep learning models achieve high performance on large-scale datasets, their generalization across different clinical domains is limited by variations in imaging protocols and patient demographics. This study aims to evaluate several deep learning architectures and investigate a transfer learning strategy to mitigate domain shift. Three architectures, including ResNet-backbone 3D U-Net, nnU-Net v2, and Swin UNETR, were benchmarked from scratch and compared with a fine-tuned nnU-Net initialized with AutoPET II weights. Results on the internal dataset showed that the fine-tuned nnU-Net achieved a Dice similarity coefficient (DSC) of 83.4 ± 6.5%, a 95% Hausdorff distance (HD95) of 5.1 ± 3.6 mm, and a precision of 89.6 ± 8.2%. Compared to the nnU-Net v2, the fine-tuned nnU-Net improved the absolute DSC by 6.8% while reducing local training time by 37.5% by bypassing the initial feature-learning phase. The fine-tuned nnU-Net model also demonstrated a high correlation between the MTV and the ground truth (Pearson r = 0.96, p < 0.001), indicating its potential as a reliable automated approach for quantitative MTV extraction and NSCLC prognostic-related analysis.

  • Open Access

    Benchmarking Deep Learning for NSCLC PET/CT Segmentation on a Histologically Confirmed Vietnamese Dataset: Validation and Generalization

    by Quang Tuan Ho, Ngoc Ha Bui, Duong Tran Thuy, Quang Huy Khuat, Ngoc Toan Tran, Xuan Chung Le, Huu Quyet Nguyen, Tat Thang Nguyen, Van Thai Nguyen, Dinh Thuy Mai, et al.

    Accurate segmentation of non-small cell lung cancer (NSCLC) on positron emission tomography/computed tomography (PET/CT) is a critical foundation for automated metabolic tumor volume (MTV) quantification and staging. Although deep learning models achieve high performance on large-scale datasets, their generalization across different clinical domains remains challenged by variations in imaging protocols and patient demographics. This study aims to evaluate several deep learning architectures and investigate a transfer learning strategy to mitigate domain shift on a dataset of 400 PET/CT scans from Vietnamese NSCLC patient cohort. Three architectures, including 3D U-Net, nnU-Net v2, and Swin UNETR, were benchmarked from scratch and compared with a fine-tuned nnU-Net initialized with AutoPET II weights. Results on the internal dataset showed that the fine-tuned nnU-Net achieved a Dice similarity coefficient (DSC) of 83.4 ± 6.5%, a 95% Hausdorff distance (HD95) of 5.1 ± 3.6 mm, and precision of 89.6 ± 8.2%. Compared to the nnU-Net v2, the fine-tuned nnU-Net improved the absolute DSC by 6.8% while reducing the training time by 37.5%. The fine-tuned nnU-Net model also demonstrated a good correlation between the MTV and the ground truth (Pearson r = 0.96, p < 0.001), indicating its potential as a reliable automated approach for quantitative MTV extraction and NSCLC prognostic related analysis.

  • Open Access

    ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ CỦA PHÁC ĐỒ BEVACIZUMAB – mFOLFOX6 TRONG ĐIỀU TRỊ BƯỚC 1 BỆNH NHÂN UNG THƯ ĐẠI TRỰC TRÀNG GIAI ĐOẠN IV

    by Nguyễn Hương Giang Trịnh, Thị Minh Châu Nghiêm, Xuân Anh Nguyễn, Quang Vinh Đặng, Vân Trường La

    Mục tiêu: Đánh giá kết quả và tác dụng không mong muốn của phác đồ Bevacizumab – mFOLFOX6 trong điều trị bước 1 bệnh nhân ung thư đại trực tràng (UTĐTT) giai đoạn IV. Đối tượng và phương pháp nghiên cứu: Hồi cứu kết hợp tiến cứu, theo dõi dọc trên 41 bệnh nhân ung thư đại trực tràng giai đoạn IV theo AJCC 8th được điều trị bước 1 bằng phác đồ Bevacizumab – mFOLFOX6 tại bệnh viện Quân y 103 và bệnh viện Trung ương Quân đội 108 từ tháng 5/2019 đến tháng 12/2023. Kết quả: Trung vị thời gian sống thêm không bệnh tiến triển là 11 tháng. Tác dụng không mong muốn thường ở mức độ 1-2. Kết luận: Phác đồ Bevacizumab – mFOLFOX6 trong điều trị ung thư đại trực tràng giai đoạn di căn có hiệu quả điều trị cao và độc tính có thể kiểm soát được